Small molecules & peptides

PSMA-1007 reference standard

Reference Standard for [¹⁸F]PSMA-1007

[¹⁸F]PSMA-1007 standard

(3S,10S,14S)-1-(4-(((S)-4-carboxy-2-((S)-4-carboxy-2-(6-fluoronicotinamido)butanamido)butanamido)methyl)phenyl)-3-(naphthalen-2-ylmethyl)-1,4,12-trioxo-2,5,11,13-tetraazahexadecane-10,14,16-tricarboxylic acid


Research Chemical


Molar mass 1031.00

CAS RN [not yet assigned]

Purity ≥ 95 %

  • colorless to off-white solid
  • soluble in dimethyl sulfoxide


CoA: appearance, ¹H NMR and ¹⁹F NMR spectra (identity), HPLC (purity)

Product sheets (PDF)


Giesel F.L. et al. ¹⁸F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. Clin. Genitourin. Cancer. 2016. doi: 10.1016/j.clgc.2016.12.029.

Giesel F.L. et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging 2017, 44(4), 678–688. doi: 10.1007/s00259-016–3573–4.

Cardinale J. et al. Preclinical Evaluation of [¹⁸F]PSMA-1007: A New PSMA-Ligand for Prostate Cancer Imaging. J. Nucl. Med. 2016. doi: 10.2967/jnumed.116.181768

Giesel F.L. et al. ¹⁸F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. Eur. J. Nucl. Med. Biol. 2016, 43, 1929–30.

Kesch C. et al. Intra-individual comparison of ¹⁸F-PSMA-1007-PET/CT, multi-parametric MRI and radical prostatectomy specimen in patients with primary prostate cancer - a retrospective, proof of concept study. J Nucl Med. 2017 doi: 10.2967/jnumed.116.18933

Add to inquiry

Product No.Filling amountQuantity
Product No.: 99433Filling amount: 5 mg
Product No.: 99433Filling amount: 10 mg
Product No.: 99433

Related products

Product was added